Physician profile
Arnold Sholder
NPI 1720087166
$683.40
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $233.22 | 2019 | |
| Janssen Biotech, INC. | $175.99 | 2019 | |
| Pfizer INC. | $127.62 | 2019 | |
| Abbvie INC. | $81.51 | 2019 | |
| Boston Scientific Corporation | $34.92 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $30.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$887.61 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Sholder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.